Free Trial

Apellis Pharmaceuticals Q1 2024 Earnings Report

Apellis Pharmaceuticals logo
$22.68 +0.81 (+3.70%)
As of 04:00 PM Eastern

Apellis Pharmaceuticals EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.54
Beat/Miss
Met Expectations
One Year Ago EPS
-$1.56

Apellis Pharmaceuticals Revenue Results

Actual Revenue
$172.33 million
Expected Revenue
$163.37 million
Beat/Miss
Beat by +$8.96 million
YoY Revenue Growth
+284.30%

Apellis Pharmaceuticals Announcement Details

Quarter
Q1 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Apellis Pharmaceuticals Earnings Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Evercore ISI Remains a Buy on Apellis Pharmaceuticals (APLS)
See More Apellis Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Apellis Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apellis Pharmaceuticals and other key companies, straight to your email.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals (NASDAQ:APLS), a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

View Apellis Pharmaceuticals Profile

More Earnings Resources from MarketBeat